Atea Pharmaceuticals (NASDAQ: AVIR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.580 | -0.510 | 0.0700 | ||||
REV | 3.330M | 0 | -3.330M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Atea Pharmaceuticals (NASDAQ: AVIR) through any online brokerage.
Other companies in Atea Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), CinCor Pharma (NASDAQ:CINC), Sundial Growers (NASDAQ:SNDL) and DICE Therapeutics (NASDAQ:DICE).
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on Wednesday, March 2, 2022. The analyst firm set a price target for 8.00 expecting AVIR to rise to within 12 months (a possible 9.44% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Atea Pharmaceuticals (NASDAQ: AVIR) is $7.31 last updated Today at June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Atea Pharmaceuticals.
Atea Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Atea Pharmaceuticals.
Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.